ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
ORIGINAL RESEARCH
Experience of tocilizumab in hospital patients with moderate COVID-19
About authors
1 Peoples’ Friendship University of Russia, Moscow, Russia
2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia
3 Clinical Hospital for Infectious Diseases №1, Moscow, Russia
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Correspondence should be addressed: Olga A. Burgasova
Volokolamskoe sh., 47, str. 8, korp. 5, Moscow, 125310, Russia; ur.liam@avosagrubaglo
About paper
Author contribution: OA Burgasova — initiative and design, supervision of the clinical part of the study, writing of the manuscript; SV Dolinniy — literature review, clinical observations, data processing; VB Tetova — literature review, editing of the manuscript; DA Ogarkova — statistical analysis; MA Odnoralov, VV Baсalin — clinical observations, processing of clinical and laboratory data; SV Smetanina — concept; NA Antipyat — supervision of the clinical part of the study, MV Taranova — literature review, data processing.
Compliance with ethical standards: the study was approved by the ethics committee at the Clinical Hospital for Infectious Diseases №1 (Protocol 1 of January 11, 2021); all participants provided informed consent for the study.
Received: 2022-03-10
Accepted: 2022-04-03
Published online: 2022-04-15
|
Table 1. Structure of clinical symptoms in patients receiving tocilizumab vs. standard therapy (+dexamethasone)
Table 2. Baseline data, dynamics of clinical and laboratory parameters, and clinical outcomes in patients receiving tocilizumab vs. standard therapy (+dexamethasone)
Table 3. Dynamics of clinical and laboratory parameters in patients treated with tocilizumab
Table 4. Dynamics of clinical and laboratory parameters in patients treated with standard therapy (+dexamethasone)
